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ABSTRACT
Purpose To formulate f-MWNTs-cationic liposome hybrids
for the simultaneous delivery of siPLK1 and doxorubicin to
cancer cells.
Method f-MWNTs-cationic liposome hybrids were prepared
by the thin film hydration method where the lipid film was
hydrated with 100 μg/ml or 1 mg/ml of ox-MWNTs-NH3
+
or MWNTs-NH3
+ in 5% dextrose. siRNA complexation and
protection ability was determined by agarose gel elec-
trophoresis. f-MWNTs and liposome interaction was
evaluated using Nile Red (NR) fluorescence spectrosco-
py. Cellular uptake in A549 cells was assessed by flow
cytometry. Silencing of target proteins was determined by
Luciferase and MTT assays. Sub-G1 analysis was performed
to evaluate apoptosis following co-delivery of siPLK1 and
Doxorubicin (Dox).
Results Zeta potential and siRNA complexation profile ob-
tained for all hybrids were comparable to those achieved with
cationic liposomes. ox-MWNTs-NH3
+ showed greater extent
of interaction with cationic liposomes compared to MWNTs-
NH3
+. ox-MWNTs-NH3
+ was able to protect siRNA from
nuclease-mediated degradation. Enhanced cellular uptake of
both the carrier and loaded siRNA in A549 cell, were ob-
served for this hybrid compared to the liposomal carrier. A
synergistic pro-apoptotic effect was obtained when siPLK1
silencing was combined with doxorubicin treatment for the
hybrid:siRNA complexes compared to the lipoplexes, in
A549 cells in vitro.
Conclusions f-MWNTs-cationic liposome hybrid de-
signed in this study can serve as a potential vehicle for
the co-delivery of siRNA and cytotoxic drugs to cancer
cells in vitro.
KEY WORDS A549 . cancer cells . gene silencing .
multi-walled carbon nanotubes . siRNA
ABBREVIATIONS
1-H ox-MWNTs-NH3
+-liposome hybrid
(f-MWNT:total lipid mass ratio
35.8%:64.2%)
1-L ox-MWNTs-NH3
+-liposome hybrid
(f-MWNT:total lipid mass ratio
5.3%:94.7%)
2-H MWNTs-NH3
+-liposome hybrid
(f-MWNT:total lipid mass ratio
35.8%:64.2%)
2-L MWNTs-NH3
+-liposome hybrid
(f-MWNT:total lipid mass ratio
5.3%:94.7%)
chol Cholesterol
CNTs Carbon nanotubes
DLSl Dynamic light scattering
DOTAP 1,2-dioleoyl-3-trimethylammonium-
propane
Dox Doxorubicin
f-CNTs Functionalized carbon nanotubes
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f-MWNTs Functionalized multi-walled carbon
nanotubes
L Liposome
Luc Luciferase
MFI Mean Fluorescence Intensity
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide
MWNT-NH3
+ Ammonium-functionalized multi-
walled carbon nanotubes
NR Nile Red
ox-MWNT-NH3
+ Ammonium-functionalized oxidized
multi-walled carbon nanotubes
PDI Polydispersity index
PLK1 Polo-like kinase 1
RISC RNA-induced silencing complex
RNAse Ribonuclease
siNEG non-coding siRNA
siRNA Small interfering RNA
SSC Sideward scattering
INTRODUCTION
Small interfering RNA (siRNA) has emerged as a therapeutic
strategy for various diseases, including cancer, due to its
target-specific gene silencing. Moreover, down-regulation of
genes that are overexpressed in tumors by siRNA presents
advantages over plasmid DNA therapy. As siRNA acts at
the cytoplasm level, it does not need to cross the nuclear en-
velope contrary to DNA which needs to be delivered to the
cell nucleus (1). However, due to its highmolecular weight and
negative charge, cellular uptake and subsequent intracellular
trafficking to the effector complex (RNA-induced silencing
complex, RISC) are hampered and represent major technical
hurdles for the efficacy of siRNA (2). Thus, in the past few
years researchers have focused on the development of suitable
delivery systems that would make clinical practice of siRNA
therapy possible. Approaches to overcome these limitations
have relied on non-viral siRNA carriers based on cationic
liposomes or polymers able to spontaneously complex and
condense genetic materials (3). Nevertheless, these systems
are characterized by a lack of efficiency accompanied by a
high level of toxicity rendering them mostly inadequate for
in vivo applications (2).
Recently, a unique type of nonviral gene vector
has emerged, based on functionalized carbon nano-
tubes (f-CNTs) (4). CNTs are ordered structures with high
aspect ratio and unique features such as high mechanical
strength, high thermal and electrical conductivity (5). In addi-
tion, during the last decade, their potential use in the biomed-
ical field has also attracted great interest due to CNTs ability
to translocate into the cytoplasm by directly crossing the plas-
ma membrane via an endocytosis-independent route where
they act like Bnanoneedles^ without inducing apoptosis
(4–6). The main problem associated with the use of CNTs is
their hydrophobicity which leads to poor dispersibility.
However, this can be circumvented by surface chemical
functionalization, improving CNTs dispersibility in physiolog-
ical media and consequently broadening the spectrum of their
potential biological applications (7–9).
In the present study, we aimed at formulating functional-
ized multi-walled carbon nanotubes (f-MWNT)-cationic lipo-
some hybrids for the co-delivery of siRNA and a cytotoxic
drug in vitro. Doxorubicin (Dox) was chosen as the model drug
as it is commonly used in the treatment of a wide range of
cancers. Polo-like kinase 1 (PLK1) is a serine/threonine kinase
with key roles in cell division and checkpoint regulation of
mitosis. PLK1 is overexpressed in several types of cancer
and correlates with high tumor grades. siRNA-mediated si-
lencing of PLK1 in several cancer cell lines was shown to result
in decreased cell viability with induction of apoptosis, defects
in several mitosis processes and G2/M phase arrest (10).
Other studies showed that PLK1 down-regulation sensitizes
cancer cells to chemotherapy and can revert chemoresistance
(11–14).
In this study, a series of f-MWNT-cationic liposome
hybrids were formulated and tested for their siRNA
binding ability, stability, cellular uptake, in vitro gene
silencing efficiency, induction of apoptosis and siPLK1
and Dox co-delivery efficiency. Liposomes consisted of
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)
and cholesterol (DOTAP:chol, 2:1 molar ratio), one of
the most widely used transfection agents. Two types of
f-MWNTs were used: MWNT-NH3
+ (−455.5 +/−
185.42 nm in length, 20–30 nm in diameter) and ox-
MWNT-NH3
+ (−277.5 +/− 152.93 nm nm in length,
20–30 nm in diameter). f-MWNT-liposome hybrids were pre-
pared at two different f-MWNT:total lipid mass ratios
(5.3%:94.7% and 35.8%:64.2%).
MATERIALS AND METHODS
Materials
Pristine MWNTs were purchased from Nanostructured and
Amorphous Materials Inc. (Houston, USA); Batch: 1237YJS
95%, outer diameters between 20 and 30 nm, and lengths
between 0.5 and 2 μm). ox-MWNT-NH3
+ (type 1) and
MWNT-NH3
+ (type 2) (Fig. 1) were functionalized using 1,
3-dipolar cycloaddition as described by Prato and co-workers
(15). 1,2-dioleoyl-3-trimethylammonium-propane (chloride
salt) (DOTAP, 99%) was obtained from Avanti Polar Lipid
(USA). Cholesterol, chloroform, methanol, dextrose, doxoru-
bicin hydrochloride (Dox), MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide), dimethylsulfoxide
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(DMSO), paraformaldehyde and Ribonuclease A from bo-
vine pancreas RNAse (R6513-50MG) were purchased from
Sigma-Aldrich (UK). 0.2 μm filter was from Millipore (UK).
Dulbecco’s modified Eagle medium (DMEM), Ham’s F-12
medium, fetal bovine serum (FBS), penicillin/streptomycin,
phosphate buffered saline (PBS), Lipofectamine 2000,
propidium iodide (PI), and agarose were purchased from
Life Technologies (Invitrogen, UK). 6× Orange Loading
Dye was from Fermentas (UK) and 0.3× GelRed stain was
from Biotium (USA). Luciferase assay kit was obtained from
Promega Corporation (Madison, WI) and BCA protein assay
kit from Thermal Scientific (UK). Noncoding siNEG and
ATTO 655-labeled siNEG (antisense sequence, 5′-CAUC
GUCGAUCGUAGCGCAA-3′, #4754184; sense sequence,
5′-GCGCUACGAUCGACGAUGGG-3′, #4754185), and
s iP lk -1 ( sequence 5 ′ -CCUUGAUGAAGAAGAU
CACdTdT-3′) were purchased from Eurogentec (Belgium).
The human epithelial lung carcinoma A549 (CCL-185) cell
line was from American Type Culture Collection (ATCC).
A549-Luc cells were purchased from Caliper (Perkin Elmer).
Silencer Luciferase siRNA (siLuc) (AM4629) was obtained
from Ambion (USA). All chemical substances and solvents
were used without further purification.
Chemical Functionalization of MWNTs
To prepare ammonium-functionalized oxidized multiwalled
carbon nanotubes (ox-MWNTs- NH3
+) type 1, pristine
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Fig. 1 Characterization of the synthesized ox-MWNT-NH3
+ (type 1) and MWNT-NH3
+ (type 2) derivatives. (a) Scheme of the synthetic route used for the
synthesis of ox-MWNT-NH3
+ derivatives. TGA analysis of the ox-MWNT (black line) and ox-MWNT-NH3
+ (red line). ox-MWNTshowed a drop in weight loss
at 150°C, due to the loss in the carboxylic groups introduced onCNTsurface, and at 600°C due to graphitic-skeleton decomposition. ox-MWNT-NH3
+ showed
an increase in the weight loss (13% at 600°C) due to the introduction of functional groups from the cycloaddition reaction. (b) Scheme of the synthetic route used
for the synthesis of MWNT-NH3
+ derivatives. TGA analysis of the pristine MWNT (black line) showed its thermal stability up to 750°C. MWNT-NH3
+ (red line)
displayed an increase in the weight loss (15% at 600°C) due to the introduction of functional groups from the cycloaddition reaction. Length distribution (mean±
SD) and median, determined from TEM measurements (n=100) are displayed on length distribution histograms.
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MWNTs were firstly oxidized under stirring for 2 h followed
by sonication in a water bath (20 W, 40 kHz) for 2 h in a
sulfuric acid/nitric acid solution (3:1v/v, 98 and 65%, respec-
tively) at room temperature. Deionized water (DI) was then
carefully added and the oxidized MWNTs were filtered
(Omnipore GTTP membrane filtration, 0.22 μm), The col-
lected black solid was washed with DI (300 mL), 5% NaOH
solution (300 mL) and methanol (200 mL) yielding 42 mg of
ox-MWNT. ox-MWNTs-NH3
+ (type 1) was subjected to the
1,3 dipolar cycloaddition reaction (16). In brief, ox-MWNT
(20 mg) were suspended in 20 ml of dimethylformamide
(DMF) and sonicated for 10 min. After sonication, the
tertiary-butyloxycarbonyl (Boc)-protected amino acid
(150 mg, 0.51 mmol) (Fig. 1a) and paraformaldehyde
(18.5 mg, 0. 51 mmol) were added stepwise (30 mg amino
acid and 3.7 mg formaldehyde every 24 h), and the mixture
was heated at 125°C for 5 days. Multiple centrifugation steps
(1811 g, 10 min) were carried out to separate the unreacted
MWNTs (remain suspended) from the f-MWNTs, which were
then filtered through a 0.2 μm PTFE filter and the collected
black solid was washed with 100 ml of dimethylformamide
(DMF) and methanol yielding 18 mg of ox-MWNT-NHBoc.
For Boc deprotection, 15 mg of ox-MWNT-NHBoc were
suspended in 10 ml DMF, and sonicated for 10 min. After
sonication, 10 ml of trifluoroacetic acid (TFA) were added to
the reaction mixture. The solution was stirred for 24 h and the
f-MWNTs were filtered through a 0.2 μm PTFE filter. The
collected black solid was washed with 10 ml of DMF and
methanol yielding 13 mg of ox-MWNT-NH3
+ (type 1) (ther-
mogravimetric analysis (TGA) mass loss of 13%, 193 μmol
functional groups/g MWNTs). ox-MWNTs-NH3
+ were dis-
persed in 5% dextrose at concentrations of 100 μg/mL and
1 mg/mL, affording 1-L and 1-H, respectively.
Ammonium-functionalized multiwalled carbon nanotubes
(MWNTs-NH3
+, type 2) were prepared directly from pristine
MWNTs following the 1,3 dipolar cycloaddition reaction as-
described above, without prior oxidation (Fig. 1b). The Boc
group was subsequently deprotected using the same protocol
shown for type 1 derivative, affording MWNTs-NH3
+ (TGA
mass loss of 15%, 529 μmol functional groups/g MWNTs).
MWNTs-NH3
+ (type 2) were dispersed in 5% dextrose at
concentrations of 100 μg/mL and 1 mg/mL, affording 2-L
and 2-H, respectively.
Thermogravimetric Analysis
MWNT samples were loaded in platinum pans and the TGA
analysis was performed using the TGA Q500 (TA instru-
ments, USA). Initially the analysis was carried out isothermal-
ly in nitrogen atmosphere at 100°C for 20 min followed by a
controlled increase in temperature at a rate of 10°C/min to
reach a maximum of 1000°C at the end of the analysis.
Length Analysis by Transmission Electron Microscopy
(TEM)
Length distribution histograms were obtained by measuring
nanotube length from transmission electron microscopy im-
ages (N=100).
Formulation of Cationic Liposomes
and f-MWNTs-Liposome Hybrids
Liposomes, L, were prepared by lipid film hydration method
followed by sonication. Briefly, DOTAP and cholesterol (2:1
molar ratio) were dissolved in chloroform:methanol (4:1v/v),
the organic solvent was evaporated in a rotary evaporator
(Buchi, Switzerland) under vacuum at 40°C for 30 min and
then flushed with a N2 stream to remove any residual traces of
organic solvent. The dried lipid film was hydrated with 1 ml of
5% dextrose and multilamellar vesicles (MLV) were reduced
in size by sonication for 2 min. Small unilamellar vesicles
(SUV) were left for at least 2 h to anneal before being used
or stored at 4°C under N2. For the preparation of hybrids 1-L,
2-L and 1-H, 2-H, the same protocol was used, but instead of
hydrating the lipid film with 5% dextrose, solutions of
100 μg/ml and 1 mg/ml of f-MWNTs in 5% dextrose were
used, affording hybrids with f-MWNT:lipid mass ratio of
5.3%:94.7 and 35.8%:64.2%, respectively. The final lipid
concentration was 2mM. Size reduction was achieved by bath
sonication for 2 min.
Electron Microscopy Imaging of the Hybrids
Low voltage STEM imaging was carried out on the FEI ex-
treme high resolution Magellan 400 L SEM running at 20 kV
fitted with a second generation FEI retractable STEM detec-
tor. This detector has multiple segments that allow capture of
different signals simultaneously. The central part of the detec-
tor collects electrons at a normal angle producing a conven-
tional bright field images. High angle annular dark field
(HAADF) images are produced from scattered electrons that
are collected on an annular dark field detector at higher an-
gles; the intensity in HAADF images is directly related to the
atomic number of the elements within the sample. Samples
were sonicated and dispersed in 5% dextrose and placed
dropwise onto a holey carbon copper support grid for
STEM observation.
Fluorescence Labelling of Cationic Liposomes
and f-MWNTs-Liposome Hybrids
Fluorescently labelled liposomes and hybrids were prepared
for fluorescence spectroscopy studies and in vitro cell uptake
studies. Nile Red (lipid probe), emitting in the red region, is
a hydrophobic fluorescent dye which was incorporated in the
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lipid bilayer of liposomes. Nile Red (NR) was added to the
lipid mixture at a ratio of 1:300 dye:lipid molecules and for-
mulations were prepared as described above. Formulations
were kept protected from light.
Physico-Chemical Characterization of Cationic
Liposomes and f-MWNTs-Liposome Hybrids
Measurement of the hydrodynamic diameter and Zeta-
potential of the prepared formulations were performed using
dynamic light scattering (DLS) with a Nanosizer ZS series
(Malvern Instruments, Southborough, MA). Disposable poly-
styrene cells and disposable plain folded capillary Zeta cells
were used. Suspensions were diluted in deionized water and
measurements were performed at 25°C. Electrophoretic mo-
bility was used to calculate the ζ -potential using the
Helmholtz-Smoluchowski equation. The hydrodynamic size
was presented as the average value of 20 runs, with triplicate
measurements within each run.
Electrophoretic Mobility Shift Assay
The ability of f-MWNTs-liposome hybrids to complex siRNA
was determined by GelRed displacement assay and agarose
gel electrophoresis. Complexes were prepared by mixing
0.25 μg (25 μl) siNEG in 5% dextrose with an equal volume
of DOTAP:chol liposomes or f-MWNTs-liposome hybrids at
different Nitrogen (N)/ Phosphate (P) molar ratios. For exam-
ple, 0.25 μg siRNA: 0.7011 μg DOTAP:Chol is equivalent to
1:1 N/P ratio. The positive charge contribution from f-
MWNT was minimal so that the f-MWNT mass was not
taking into account when calculating the N/P ratio. For com-
parison, 0.25 μg of siRNA was also mixed with f-MWNTs at
equivalent ratios used in the hybrid. Complexes were in-
cubated at room temperature for 30 min to allow com-
plete formation. Naked non-coding siRNA (siNEG,
0.25 μg) was included for comparison. After staining with
6× Orange Loading Dye, the suspensions were loaded
onto 1% (w/v) agarose containing 0.3× GelRed stain,
followed by electrophoresis in 0.5× Tris-Borate-EDTA
buffer (SigmaAldrich, UK) at 80 mV for 50 min. The gels
were then visualized under UV light using ChemiDoc MP
system (BioRad, UK).
Nile Red Fluorescence Spectroscopy
NR fluorescence spectroscopy was used to study the interac-
tion between the f-MWNTs and cationic liposomes in the
formed hybrids. The fluorescence and emission spectra of
Nile Red was measured using FLUOstar Omega (BMG
labtech, UK) plate reader at excitation and emission wave-
lengths of 544 nm and 610–620 nm, respectively. A calibra-
tion curve using DOTAP:cholesterol liposome incorporating
Nile Red (L) at a ratio of 1:300, dye:lipid molar ratio was
established to confirm that fluorescence values were within
the linear range of the instrument (data not shown).
Different amounts of liposomes were used so that NR concen-
trations ranged from 0 to 1 μg/ml. Formulations were pre-
pared as described above. This protocol was referred to as the
Bencapsulation protocol^. To exclude the quenching effect of
f-MWNTs on the dye, control samples were prepared where
NR was mixed with f-MWNTs in 5% dextrose (quenching
control). Another control group was included in this experi-
ment where f-MWNTs were mixed just before measurement
with the preformed liposomes containing NR, at equivalent
concentrations used in the encapsulation protocol. This pro-
tocol was referred to as the Bmixing protocol^. For NR fluo-
rescence measurements, 20 μl of each formulation (quenching
control, encapsulation or mixing protocols) were diluted 5× to
a final volume of 100 μl, yielding final lipid and NR concen-
trations of 0.6 mM and 0.625 μg/ml, respectively.
In Vitro siRNA Stability in Serum
The extent of enzymatic degradation mediated by serum nu-
cleases was analyzed by incubation of non-coding siRNA
(siNEG) complexed with formulations L and hybrids 1-L, 1-
H, 2-L, and 2-H with FBS. The complexes were prepared as
described above, at N/P charge ratio of 4:1 as siRNAwas fully
complexed at this ratio as determined by the electrophoretic
mobility shift assay. After complexation, FBS (5 μl) was added
to the complexes at a final concentration of 50% (v/v) and
samples were incubated at 37°C for 1 h or 4 h. To keep the
same volume and incubation time as that used in the heparin
competition assay, 5 μl of 5% dextrose were added to each
sample and samples were further incubated at 37°C for
10 min. After incubation, the reaction was terminated by
adding EDTA to a final concentration of 50 mM. Non-
incubated naked siRNA (0.25 μg) or naked siRNA (0.25 μg)
co-incubated with FBS (50% v/v) and EDTA (50 mM) were
used as negative and positive controls, respectively. Samples
were electrophoresed under the conditions described above.
In Vitro siRNA Protection Against RNAse
The siRNA (siNEG) protection ability of formulations L and
hybrids 1-L, 1-H, 2-L, and 2-H from RNAse was assessed.
The complexes at N/P charge ratio of 4:1 were prepared as
described above. After complexes were formed, RNAse (5 μl)
was added to the complexes at a final concentration of
0.4 μg/ml and samples were incubated at 37°C for 10 min
or 1 h. To keep the same volume and incubation time as that
used in the heparin competition assay, 5 μl of 5% dextrose was
added to each sample and samples were further incubated at
37°C for 10 min. After incubation, the reaction was terminat-
ed by adding EDTA to a final concentration of 50 mM. Non-
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incubated naked siRNA (0.25 μg) or naked siRNA (0.25 μg)
co-incubated with RNAse (0.4 μg/ml) and EDTA (50 mM)
were used as negative and positive controls, respectively.
Samples were electrophoresed under the conditions described
above.
Heparin Competition Assay
A heparin competition assay was performed to dissociate
siRNA (siNEG) complexes in order to examine the siRNA
integrity following incubation either with FBS or with
RNAse. Following incubation with either FBS or RNAse,
heparin was added to each sample to a final concentration
of 50 IU/ml and samples were further incubated at 37°C
for 10 min. After incubation, the reaction was terminated by
adding EDTA to a final concentration of 50 mM. Non-
incubated naked siRNA (0.25 μg) or naked siRNA (0.25 μg)
with RNAse (0.4 μg/ml), heparin (50 IU/ml) and EDTA
(50 mM) were used as negative and positive controls, respec-
tively. Samples were electrophoresed under the conditions
described above.
Cell Culture
Epithelial lung carcinoma cells (A549) were cultured in
Ham’s F-12 supplemented with 10% FBS, 50 U/ml peni-
cillin, 50 μg/ml streptomycin, 1% L-glutamine, at 37°C
in 5% CO2. Luciferase expressing A549 cells (A549-Luc)
were cultured in Ham’s F-12 supplemented with 10%
FBS, 1% L-glutamine, at 37°C in 5% CO2. Cells were
routinely grown in 75 cm2 canted-neck tissue culture
flasks and passaged twice a week using 0.05% Trypsin/
EDTA when reaching 80% confluency in order to main-
tain exponential growth.
siRNAUptake Studies in A549 Cells by FlowCytometry
A549 cells were subcultured onto 24-well plates (5x104cells/
well) for 24 h prior transfection with liposome/siRNA or
hybrid/siRNA complexes. Cells were incubated with com-
plexes in serum-free and antibiotics-free medium for 4 h, after
which serum was added to make the final concentration of
serum to 10% (v/v). Cells were allowed to interact with the
complexes for 24 h at 37°C in a humidified atmosphere (5%
CO2) incubator. After incubation, cells were washed twice
with PBS to remove unbound complexes, trypsinized, centri-
fuged at 800 g for 5 min, resuspended in PBS, and analyzed
by flow cytometry. Whenever cells were not analyzed imme-
diately, they were fixed in 4% (v/v) paraformaldehyde in PBS
solution and stored at 4°C. Bivariate and univariate histo-
grams were set using the BD FACSCalibur flow cytometer
(Becton Dickinson, Franklin Lakes, NJ, USA) equipped with
CellQuest Pro software (BD,USA). Ten thousand events were
acquired in the gated cell population of interest. For NR-
labelled liposomes or hybrids, cell uptake was assessed by
NR fluorescence emission (FL-3 detector) and also by side-
ward scattering (SSC) as described previously (17, 18).
Unlabeled non-coding siRNA (siNEG) was used in these ex-
periments. For tracking siRNA internalization, ATTO 655-
labelled siNEG was used in combination with non-
fluorescently labelled L or the hybrids. ATTO 655-siNEG
uptake was measured using FL-4 detector.
Side Scatter Analysis (Complexity) in A549 Cells
by Flow Cytometry
In the bivariate scatter histograms, the sideward scattering
(SSC Lin, ordinate) vs. forward scattering histogram (FSC
Lin, abscissa) was obtained. The forward scatter and side scat-
ter detectors voltage had to be set in a way that both the
negative control (a sample containing cells without any treat-
ment) and the positive control cells (a sample containing cells
that were transfected with DOTAP:chol/siRNA complexes)
could be visualized inside the scatter dot plot. The population
containing cells only was selected to include all the cells being
studied and exclude any cell debris. In order not to include f-
MWNTs in the cell population group, a suspension contain-
ing the highest concentration of f-MWNTs without any cells
was run first to exclude any free CNT from the cell popula-
tion. The univariate histograms of cell number (counts, ordi-
nate) vs. either the sideward scattering intensity (SSC Lin,
abscissa) or the fluorescence intensity (FL-3 Log for NR fluo-
rescence or FL-4 Log for ATTO 655 fluorescence, abscissa)
were plotted and gated for the cell population. The mean
sideward scattering intensity values (SSC Lin) or the mean
fluorescence intensity values (FL-3 and FL-4 Log) were re-
corded and used for comparison.
Luciferase Expression in A549-Luc Cells
A549-Luc cells were seeded onto 96-well plates (1x104 cells/
well) with antibiotics-free F-12 medium 24 h prior transfec-
tion. The next day, siLuc or siNEG (10 μl) was complexed
with an equal volume of formulations (L or 1-L) in 5% dex-
trose at N/P charge ratio of 4:1. Following incubation at room
temperature for 30min, complexes were diluted in serum-free
and antibiotics-free medium and added to the cells to achieve
a final siRNA concentration of 80 nM. After 4 h, serum was
added to reach 10% (v/v) final serum concentration. At 48 h
post-transfection, cell lysate was prepared and luciferase ex-
pression was assayed with a Luciferase assay kit using a
luminometer FLUOstar Omega (BMG labtech, UK) plate
reader. Briefly, cells were washed with PBS before addition
of 60 μl of lysis buffer. Two freeze-thaw cycles were performed
to ensure complete cell lysis and cells were directly centrifuged
in the 96-well plate for 30 min at high speed and 4°C. 20 μl of
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the supernatant containing proteins was mixed with 100 μl of
luciferase assay reagent and then luminescence signals were
recorded. 20 μl of the lysate was used to determine the protein
concentration using a BCA protein assay kit, following man-
ufacturer’s instructions. The Luciferase activity was calculated
as RLU/mg protein. Values were normalized to siNEG
transfected cells.
Biological Activity of siPLK1 in A549 Cells With MTT
Assay
In order to assess the functionality of siRNA delivered by L or
1-L, a functional siRNA (siPLK1) was used and toxicity in-
duced by PLK1-specific gene silencing was determined. A549
cells were seeded onto 96-well plates (1×104 cells/well) with
antibiotics-free F-12 medium 24 h prior transfection. The
next day, siPLK1 or siNEG (10 μl) was complexed with an
equal volume of the formulation (L or 1-L) in 5% dextrose at
N/P charge ratio of 4:1. Lipofectamine 2000 was used as a
positive control for the transfection, whereas cells treated with
10% DMSO were used as a cytotoxic control for the MTT
assay. Following incubation at room temperature for 30 min,
complexes were diluted in serum-free and antibiotics-free me-
dium and added to the cells, yielding a final siRNA concen-
tration of 80 nM. After 4 h, serum was added to reach 10%
(v/v) final serum concentration. At 48 h post transfection,
MTT assay was performed. Cells were incubated with MTT
solution at 0.5 mg/ml MTT final concentration for 3 h.
Media was then removed and the formazan produced was
dissolved in 200 μl DMSO and absorbance was read in a
FLUOstar Omega (BMG labtech, UK) plate reader at
560 nm. Results were expressed as the percentage of cell via-
bility (mean±SD) and normalized to siNEG transfected grow
of each carrier. The following equation was used: % cell
viability=(A560 nm of siPLK1 transfected cells/ A560 nm
of siNEG transfected cells)×100.
Apoptosis Measurement and Sub-G1 Analysis
with Flow Cytometry
In order to assess the effect of combining PLK1 down-
regulation with Dox toxicity using the different formulations
on cell apoptosis (as a therapeutic endpoint), sub-G1 analysis
was carried out by flow cytometry. MWNT has been reported
to interfere with MTT assay so it was avoided here (19). A549
cells were seeded onto 24-well plates (5x104 cells/well) for 24 h
prior transfection. The next day, siPLK1 or siNEG was com-
plexed with equal volume of formulation (L or 1-L) in 5%
dextrose at N/P charge ratio of 4:1. An equal volume of
Dox was added to each complex and allowed to complex with
MWNT for 30 min at room temperature, yielding a final Dox
concentration of 1 μM. Cells were then incubated with the
complexes (with or without Dox) in antibiotics-free medium
for 48 h at 37°C in a humidified atmosphere (5% CO2) incu-
bator. After incubation, both attached cells and those in sus-
pension were harvested, washed in PBS and fixed with cold
70% (v/v) ethanol for at least 1 h, at 4°C. Following fixation,
cells were centrifuged at 850 g for 5 min at 4°C to remove
ethanol. The cells were then resuspended in PBS:citrate buffer
(1:1v/v) and incubated for 5 min at 37°C. After incubation,
supernatant was removed by centrifugation at 850 g for 5 min
at 22°C. The cells were then resuspended in PBS solution
containing propidium iodide (50 μg/ml) and RNAse
(100 μg/ml) and incubated in the dark for 30 min at 37°C.
Cells were then analyzed by BD FACSCalibur flow
cytometer. The percentage of events in the sub-G1 phase of
the cell cycle histogram (10,000 events) was determined using
CellQuest Pro software (BD, USA).
Statistical Analysis
Data are presented as means±standard deviation (SD). The
statistical analysis was performed using one-way ANOVA
followed by Tukey’s multiple comparison test (GraphPad
Prism 5.0 software). Differences between groups were consid-
ered significant for *p<0.05, highly significant for **p<0.01
and extremely significant for ***p<0.001.
RESULTS
Physicochemical Characterization
of f-MWNTs-Liposome Hybrids
Initially the length distribution of the f-MWNTwas performed
fromTEM images (n=100). The length of the pristineMWNT
is provided by the supplier (0.5–2 μm). In case of oxidized
MWNT (type 1), pristine MWNT is subjected to acid treat-
ment step which results in shortening to 277.5 +/− 152.93 nm
(20). In case of type 2 where no oxidation step was performed,
the length was 455.5 +/− 185.42 nm. Cycloaddition reaction
is not expected to reduce the length of MWNT (15), however,
the centrifugation and filtration steps during functionalization
leads to exclusion of longer tubes.
TGA is a technique widely used to characterize materials
with different thermal stabilities. It was therefore used here to
quantify the degree of chemical functionalization with organic
functional groups (Fig. 1). In Fig. 1a, ox-MWNT-NH3
+ (type
1, red line) showed a drop in weight loss at 150°C, due to the
loss in the carboxylic groups introduced on CNT surface, and
at 600°C due to graphitic-skeleton decomposition. ox-
MWNT-NH3
+ showed an increase in the weight loss of
13% at 600°C confirming the introduction of functional
groups from the cycloaddition reaction. Pristine MWNTs
were thermally stable up to 750°C (Fig. 1b, black line).
MWNT-NH3
+ (type 2) (Fig. 1b, red line) displayed an increase
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in the weight loss of 15% at 600°C also due to the introduction
of functional groups from the cycloaddition reaction. The de-
gree of chemical functionalization for ox-MWNT-NH3
+
(type 1) and MWNT- NH3
+ (type 2) was calculated as
193 μmol and 529 μmol functional groups/g MWNTs,
respectively.
Physicochemical characterization of the four hybrids was
also carried out to determine their feasibility as co-delivery
systems. The composition, hydrodynamic diameter, polydis-
persity index (PDI) and ζ-potential of the different formula-
tions tested are summarized in Table I. The hydrodynamic
diameters of all formulations tested were, on average, less than
200 nm, with all f-MWNT-liposome hybrids showing greater
sizes compared to cationic liposome (L). The reported hydro-
dynamic diameters of all hybrids were surprisingly smaller
than the length of the corresponding MWNT (Fig. 1). An
explanation for this could be the fact that the hydrodynamic
diameter (Z-average) reflects a combined overall value and
not the magnitude of just one dimension of the nanocarriers
(21). Therefore, since the f-MWNTs are not spherical particles
and their diameter is much smaller (20–30 nm) compared to
their length, the hydrodynamic diameter of hybrids reflects a
combined outcome of the two dimensions. Although DLS is
not the best technique to measure the size of CNTs, we used
this method as PDI values were indicative of the size distribu-
tion. PDI of hybrids 2-L and 2-H, formed with MWNT-
NH3
+, was greater than for those formed with ox-MWNT-
NH3
+ (hybrids 1-L and 1-H). This was expected as the CNTs
that form hybrid type 2 are longer than the CNTs that form
hybrid type 1.
All formulations displayed positive ζ-potential values, rang-
ing from 32 to 52 mV, comparable to that of cationic lipo-
somes (48 mV).
Morphological Studies
The morphology of the liposomes and hybrids was studied by
low voltage STEM at 20 kV. This operating voltage allowed
us to study the structure of these beam sensitive samples
avoiding the knock-on damage occurring at higher operating
voltages (>80 kV).
Sample L showed round features of 60–200 nm in diame-
ter in agreement with the hydrodynamic diameter of the cat-
ionic liposomes (Fig. 2). The cationic liposomes were found in
micron-size agglomerates most probably formed upon solvent
drying during the TEM grid preparation.
STEM images of sample 1H (Fig. 2 and S1) showed a clear
interaction of the cationic liposomes with MWNTs. Round
features with faint contrast corresponding to the cationic lipo-
somes were present close to the ox-MWNT-NH3
+ and even
embedding them.
AFM height images, in 2D and 3D for L and 1-H are
shown in Fig. S2. Cross-section analysis exhibited height of
5–10 nm for both samples indicating the collapse of the lipo-
somes on the mica surface. Samples 1-H showed more het-
erogeneous structures compared to liposome sample.
siRNA Binding
The ability of the f-MWNT-liposome hybrids to complex
nucleic acids and the optimum N/P ratio required for com-
plexation were determined using an electrophoretic mobility
assay across a range of N:P charge ratios from 0.5:1 to 8:1.
The siRNA complexation profile of 1-L, 1-H, 2-L, and 2-H is
shown in Fig. 3. DOTAP:chol liposomes (formulation L) and
f-MWNTs were used as controls. DOTAP:chol liposomes and
hybrids 1-L, 1-H, 2-L, and 2-H present a similar complexa-
tion profile, where full siRNA complexation was achieved at
N/P ratio of 4:1, demonstrated by the absence of free siRNA
band and concomitant increased fluorescence in the well.
These results are in agreement with those obtained for ζ-
potential measurements, where the overall surface charge of
the hybrids remained unaltered upon hybridization with f-
MWNTs. Therefore, it was expected that carriers ability to
form complexes with siRNA would not be affected upon hy-
brid formation. This confirms the suitability of using the hy-
brids for siRNA delivery. f-MWNTs complexation profile in
Fig. 3 represents the equivalent f-MWNTs amount present in
the hybrid at the N/P ratios studied, which as expected
afforded N/P ratios lower than those required to achieve
complexation.
Table I Physico-chemical characterization of the hybrids.
Formulation CNT final concentration
(μg/mL)
Formulation composition
CNT:total lipid (w/w%)
Hydrodynamic
diameter±SD (nm)
Polydispersity
index
ζ-potential±SD
(mV)
L 0 0 : 100 118.9±1.83 0.256 48±5.82
Hybrid 1-L 100 5.3 : 94.7 185.9±1.12 0.319 52.4±3.45
Hybrid 1-H 1000 35.8 : 64.2 167.1±0.78 0.256 47.4±0.80
Hybrid 2-L 100 5.3 : 94.7 166.4±2.22 0.411 31.9±1.80
Hybrid 2-H 1000 35.8 : 64.2 198.9±4.15 0.354 51.8±1.87
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Nile Red Fluorescence Spectroscopy
Nile Red (NR) is a benzophenoxazone dye commonly used to
study the interaction with lipid bilayers (22). It is hypothesized
that when NR exists in non-polar environment, its fluores-
cence increases. A reduction in NR fluorescence in the hybrid
form compared to liposome can be attributed to interactions
between f-MWNT and liposome. The following groups were
included in the study (Fig. 4): (i) NR mixed with f-MWNTs in
5% dextrose (quenching controls), (ii) NR incorporated into
liposome during its formation then mixed with f-MWNT just
before measurement (mixing control), (iii) NR incorporated
into f-MWNT-liposome hybrid during its formation (encap-
sulation protocol). NR fluorescence intensities were monitored
over a period of 24 h.
After 24 h incubation, f-MWNT 1-L and 2-L (Fig. 4a),
showed a reduction of 22.8 and 9% in NR fluorescence inten-
sity, respectively, compared to NR in 5% dextrose. When
L
1-
H
Fig. 2 Morphological examination
of L and 1-H. Low voltage STEM
images of liposomes (L) and the
1-H hybrid.
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Fig. 3 Electrophoretic mobility shift assay of the different formulations complexed with siRNA at various N/P ratios. Charge ratios are calculated for a fixed siRNA
amount of 0.25 μg. Lane 1 – naked siRNA (0.25 μg), Lanes 2–6 – complexes at different N/P ratios.
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Fig. 4 NR fluorescence spectroscopy for (a) NRmixedwith f-MWNTs in 5%dextrose (quenching controls), (b) NR used in encapsulation protocol (the lipid film
containing NR is hydrated with the f-MWNTs), (c) NR used in the mixing protocol (f-MWNTs were mixed with the pre-formed labelled liposomes) over time.
NR fluorescence was detected at excitation and emission wavelengths of 544 nm and 610–620 nm, respectively. Fluorescence intensity values were measured at
0, 7 and 24 h. Results were expressed as means±SD, n=3.
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higher concentrations of f-MWNT 1-L and 2-L were used,
mimicking their content in 1-H and 2-H hybrids, NR fluores-
cence reduced by 84.3 and 91.2%, respectively. In case of the
hybrids prepared at a ratio of 5.3% (w/w) (Fig. 4b and c), when
incubation time increased from 0 to 24 h, hybrid 1-L and 2-L
showed reductions in NR fluorescence intensity by 82.7 and
70.3%, respectively, compared to L. This suggests that both
types of f-MWNTs exhibited interactions with DOTAP:chol
liposomes. NR quenching started to be seen at high f-
MWNT concentrations (equivalent to 35.8% w/w) in both f-
MWNTs and the hybrids (>84% reduction in fluorescence)
(Fig. 4b and c). In summary, NR spectroscopy studies suggest
that the lower NR fluorescence intensities obtained for the hy-
brids, of low f-MWNT content, compared to cationic lipo-
somes could be a result of the interaction between f-MWNTs
and liposomes. Conclusions on interactions could not be made
at in 1-H and 2-H due to possibility of quenching.
f-MWNT-Liposome Hybrids Stability Against Serum
and RNAse
The ability of the different f-MWNT-liposome hybrids to pro-
tect siRNA from nuclease mediated degradation was evaluat-
ed by challenging the siRNA complexes with serum. Naked
siRNA, liposome/siRNA and hybrid/siRNA complexes were
incubated at 37°C in 50% serum for 1 h or 4 h. As shown in
Fig. 5a, after 4 h incubation with serum, naked siRNA was
almost completely degraded, whereas both liposome and
hybrids prolonged siRNA stability in serum at 4:1 N/P ratio.
The heparin competition assay further confirmed that
complex formation stabilized and protected siRNA in
serum (Fig. 5b). The siRNA bands appeared at the
same position as the control bands after dissociation of
the siRNA/liposome or siRNA/hybrid with comparable
intensities. Furthermore, incubation with serum up to
4 h did not seem to significantly affect the stability of
these complexes.
The ability of complexes to protect siRNA against a ribo-
nuclease (RNAse) was conducted by incubation for 10 min or
60 min at 37°C. As shown in Fig. 5c, naked siRNA was
completely degraded after 10 min incubation with RNAse,
whereas both liposome and hybrids prolonged siRNA stability
in RNAse at 4:1 N/P ratio, demonstrated by the fluorescence
in the wells. Following siRNA release mediated by heparin,
hybrids 1-L and 2-L showed siRNA band intensities compa-
rable to that of liposome (L) at the respective incubation times
(Fig. 5d). In contrast, the extent of siRNA degradation by
RNAse was higher for hybrids prepared with high concentra-
tion of f-MWNTs, in particular for 2-H which was unable to
protect siRNA from digestion at both time points. It is evident
that 2-H complexes are least stable compared to complexes
formed with other hybrids thus, offering lowest siRNA protec-
tion against both serum and RNAse. This result is in agree-
ment with NR fluorescence measurements where MWNT-
NH3
+ displayed a lower degree of interaction with cationic
liposomes compared to ox-MWNT-NH3
+. Interestingly,
Naked siRNA 
Naked siRNA 
+RNAse
d
(min) 0 10 60 10 60 10 60 10 60 10 60 10 600
L 1-L 2-L 1-H 2-H
(h) 0 0 1 4 1 4 1 4 1 4 1 4 1 4
Naked siRNA 
+50% FBS
L 1-L
a
2-L 1-H 2-H
(h) 0 0 1 4 1 4 1 4 1 4 1 4 1 4
Naked siRNA 
+50% FBS
b
2-L 1-H 2-H1-LL
Naked siRNA  
+RNAse
c
(min) 0 10 60 10 60 10 60 10 60 10 60 10 600
L 1-L 2-L 1-H 2-H
Fig. 5 Agarose gel electrophoresis for complexes subjected to (a) serum; (b) serum followed by heparin competition assay of the different formulations
complexed with siRNA at 4:1 N/P ratio; (c) RNAse; (d) RNAse followed by heparin competition assay of the different formulations complexed with siRNA at
4:1 N/P ratio. The complexes were prepared at a fixed siRNA amount of 0.25 μg. Complexes were incubated with 50% (v/v) FBS (1 h or 4 h) or RNAse (10 min
or 60 min) at 37°C. For the heparin competition assay, complexes were further incubated for 10 min in the presence of 50 IU/mL heparin. 50 mM EDTA was
used to inactivate serum proteins. In (a), (b) Lanes 1 and 2 (far left)– naked siRNA or naked siRNA+FBS+heparin+EDTA, respectively. In (c), (d) Lanes 1 and 2
(far left)– naked siRNA or naked siRNA+RNAse+heparin+EDTA, respectively.
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although all hybrids tested demonstrated similar siRNA com-
plexation profiles, their siRNA protection capacities were dif-
ferent, indicating different stabilities, with the hybrids pre-
pared with the lowest concentration of f-MWNTs presenting
the most prominent protection ability which was comparable
to that of L. As hybrid 2-H did not appear to be very stable,
hybrid type 2was not included in the subsequent experiments.
Furthermore, hybrids with lowest f-MWNT amount were
preferred so next set of experiments was focused on hybrid
1-L.
ATTO 655-siRNA and Hybrid Cellular Uptake in A549
Cells
To study the uptake of complexed hybrids in human A549
monolayers, DOTAP:chol/siRNA or 1-L/siRNA complexes
were incubated with cells for 24 h. The uptake of the carrier (L
or 1-L) was monitored by measuring Mean Fluorescence
Intensity (MFI) of NR (FL-3) by flow cytometry. Uptake of
ATTO 655 labelled-siNEG (emitting at λem=684 nm)/(FL-
4) allowed siRNA uptake quantification. Side scatter was used
to monitor changes in cell complexity reflecting extent of f-
MWNTuptake as we reported previously. Interestingly, when
cells were allowed to interact with the hybrid complexes for
24 h, a significant increase in the sideward-scatter (SSC) by
cells was observed compared to the naive (untreated cells) or
cells treated with L complexes (Fig. 6a and b). In line with
the SSC results, cells incubated with 1-L/siNEG com-
plexes displayed higher NR fluorescence than those in-
cubated with L/siNEG complexes (Fig. 6c). Fluorescently
labelled ATTO 655 siNEG was further employed to
assess the siRNA delivery capacities of 1-L compared
to L, and to confirm if differences between the two
delivery systems could actually be seen. Figure 6d rep-
resents MFI (FL-4) of cells incubated with ATTO655 com-
plexes after 24 h incubation with cells. A significantly higher
siRNA uptake (~3 fold increase) was observed for 1-L com-
pared to L, consistent with the results obtained for NR labelled
carriers.
Functional Gene Silencing in A549 Cells
The ability of f-MWNT-liposome hybrids to effectively silence
a particular gene was studied using two experimental setups
that evaluated gene silencing activity. First, A549-Luc
cells were transfected with siLuc (siRNA that silence
the non-functional Luciferase gene) using L or 1-L
(Fig. 7a). A comparable level of Luciferase silencing
was achieved at 48 h by the two systems of 48.4%±
11.1 (L) and 49.6%±9.6 (1-L). Consistent with the results
obtained for Luciferase silencing, L and 1-L induced compa-
rable levels of PLK1 silencing which resulted in -20% cell kill
at 48 h post-transfection (Fig. 7b).
siPLK1 and Doxorubicin Co-Delivery to A549 Cells
To assess the feasibility of the new hybrids as co-delivery sys-
tems, we next carried out sub-G1 analysis to evaluate cellular
apoptosis induced by PLK1 depletion and Dox toxicity using
L and 1-L (Fig. 8). A549 cells were incubated with liposomal
system L and 1-L complexed with siPLK1 (with or without
1 μM Dox) and sub-G1 analysis was performed using flow
cytometry after 48 h of incubation. Cells incubated with
1 μM Dox or transfected with siPLK1 as a single agent were
used as positive controls. Interestingly, when Dox and siPLK1
were co-delivered to A549 cells, a synergistic effect was
achieved with both carriers L and 1-L. More importantly,
the synergism between siPLK1 and Dox dual therapy was
significantly more pronounced when the two agents were de-
livered by 1-L (40.3%±1.5 apoptotic cells) compared to sys-
tem L (26.0%±4.3 apoptotic cells).
DISCUSSION
Several studies reported that the co-delivery of a chemother-
apeutic agent and siRNA significantly enhances the cytotox-
icity to cancer cells and has great potential to overcome the
drug resistance. This approach also reduces the side effects of
chemotherapy as lower dosages of the cytotoxic drug are
needed to achieve similar therapeutic effect. However, reports
on delivering siRNA simultaneously with a conventional anti-
cancer drug to cancer cells for enhanced chemotherapy effi-
cacy have been scarce, due to the lack of efficient co-delivery
methods (23, 24). Due to PLK1 altered expression in a wide
range of cancers and to its roles in cancer progression, it was
the chosen target to siRNA therapy. The cationic nature of
liposomes is essential to efficiently complex the negatively
charged siRNA via electrostatic interactions and for interac-
tion with the negatively charged cell membrane.
Recently, Karchemski et al. reported the use of CNTs-
liposomes conjugate in an attempt of combining the efficient
cell uptake of CNTs with the well-known high drug loading
capacity of liposomes, which may result in the prevention of
potential adverse systemic side effects as lower amount of
CNTs are required while enhanced cellular uptake can still
be obtained (25). In another study, Miyako et al. successfully
developed self-assembled CNT-liposome supramolecular
nanotrains, which function as intelligent molecular-transport
systems. Utilizing the photothermal property of CNTs and the
temperature-responsive property of liposomes, controlled re-
leased was achieved by illumination of laser causing the de-
struction of liposome and therefore the release of its cargo (26).
By taking advantage of the highly efficient cellular uptake and
siRNA delivery of cationic liposomes and the high drug load-
ing capacity of CNTs and their ability to shuttle cytotoxic
drugs into cells, we aimed at formulating f-MWNTs-cationic
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Fig. 6 Analysis of cellular uptake of
DOTAP:chol liposomes (L) and
ox-MWNT-NH3
+-DOTAP:chol
hybrid (1-L) and complexed with
siRNA in A549 cells using flow
cytometry. (a) Bivariate scatter
histograms of the sideward-
scattering (SSC, Y-axis) versus
forward-scattering (FSC, X-axis), (b)
Mean sideward-scattering and (c)
Mean Fluorescence Intensity of NR
labelled L or 1-L complexed with
non-fluorescent siNEG. (d) Mean
Fluorescence Intensity of ATTO
655-labelled siNEG complexed
with unlabeled L or 1-L. Flow
cytometry analysis was performed
after 24 h incubation with
complexes. Experiments were
done in triplicates and expressed as
mean±SD (n=3).
Fig. 7 Analysis of gene silencing efficiency of DOTAP:chol liposomes (L) and ox-MWNT-NH3
+-DOTAP:chol hybrid (1-L). (a) Relative luciferase activity in
A549-Luc cells transfected with L or 1-L complexed with non-coding siRNA (siNEG) or siRNA targeting Luciferase (siLuc). Cells were collected for luciferase and
BCA assays 48 h post-transfection. (b) Cell viability (%) determined byMTTassay after 48 h transfection with L and 1-L complexed with siNEG or siPLK1. Results
were expressed as mean±SD (n=5).
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liposome hybrids for the simultaneous delivery of siRNA and
an anticancer drug to cancer cells.
We demonstrated that siPLK1 delivery by 1-L led to sig-
nificant silencing of the target protein and that a synergistic
effect was achieved when Dox and siPLK1 were co-delivered
to A549 cells in vitro. All hybrids displayed ζ –potential values
comparable to that of cationic liposomes (Table I) which in-
dicates that f-MWNTs incorporation did not affect the overall
cationic surface charge of the final hybrids formed and so that
they could still be used to complex siRNA. The minimal N/P
ratio for full complexation of siRNA and f-MWNT-cationic
liposome hybrids was found to be 4:1 (Fig. 3), similar to that
obtained for cationic liposome and consistent with previous
studies.
The fact that the overall charge of liposome and complex-
ation ability was not affected upon hybrid formation suggests
that f-MWNTs were not associated with the liposome surface,
so hydrophobic interactions were proposed. To address this
question, NR fluorescence spectroscopy was carried out to
investigate the nature of interaction between f-MWNTs and
cationic liposomes. If the interaction of the f-MWNTs is to
occur with the lipid bilayer, this should cause a localized dis-
ruption in its environment thus altering its microenvironment
polarity and therefore changing the spectral characteristics of
NR. We hypothesize that upon interaction of liposomes with
f-MWNTs, the bilayer becomes leakier and hencemore polar,
leading to a decrease in NR fluorescence intensity. The fact
that NR fluorescence was lower for all hybrids, of low f-
MWNT content, compared to L could indicate the presence
of interaction between the f-MWNTs and cationic liposomes.
The quenching of dye fluorescence in the presence of CNTs
was seen at high f-MWNT concentrations agreeing with a
previously reported study (27).
Instability poses a major problem in siRNA applications
because it degrades in serum within only a few minutes. We
tested the ability of the different f-MWNT-liposome hybrids
to protect siRNA from nuclease mediated degradation by
challenging the siRNA complexes with serum and RNAse.
Agarose gel electrophoresis results (Fig. 5) indicated that hy-
brids 1-L, 1-H, and 2-L confer similar siRNA protection abil-
ities to cationic liposomes under test conditions. On the other
hand, siRNA complexes formed with hybrid 2-H seem to be
less stable, proved by the lower intensity of siRNA bands com-
pared to all other bands. A possible explanation for the lowest
stability of hybrid 2-H and hence the reduced protection abil-
ity may be due to the poor dispersibility of MWNT-NH3
+ in
aqueous solution, potentially leading to particle aggregation
and consequent disruption of liposome structure. This result is
consistent with NR fluorescence data where MWNT-NH3
+
displayed a lower degree of interaction with cationic lipo-
somes compared to ox- MWNT-NH3
+. Taking into account
the low stability of hybrid type 2 and the fact that lower
amounts of CNTs are preferred, next experiments were car-
ried out with hybrid 1-L.
To study the uptake of carriers L and 1-L and of siRNA in
A549 cells, NR and ATTO 655 labeled-siNEG fluorescence
weremonitored, respectively. SSC results showed increased cell
complexity for 1-L compared to L (Fig. 6a and b), suggesting
enhanced cell uptake with 1-L. Furthermore, cells incubated
with 1-L complexes showed increased NR and ATTO 655
fluorescence compared to L (Fig. 6c and d). The enhanced
siRNA uptake with this hybrid could be due to enhanced cel-
lular internalization (compared to L) (Fig. 6b). Overall, the en-
hanced cellular uptake of the f-MWNT-cationic liposome hy-
brid compared to cationic liposomes alone revealed a promis-
ing relevance of this system for the delivery of genetic material.
Although cell uptake was improved when siRNA was de-
livered by 1-L compared to L, both Luciferase and PLK1
silencing experiments revealed comparable gene silencing ac-
tivity of 1-L and L (Fig. 7a and b).
1-L was then utilized as a co-delivery system for the delivery
of siRNA and a cytotoxic drug in vitro. The rationale behind
combining PLK1 silencing with chemotherapy was that com-
bined therapies may prolong G2/M phase arrest, rendering
cells more prone to apoptosis instead of mitotic slippage (28).
Sub-G1 analysis was performed in A549 cells to evaluate cellu-
lar apoptosis induced by PLK1 depletion and Dox toxicity
using L and 1-L. It is possible that Dox interacts with
MWNTs via Π-Π stacking of Dox aromatic chromophore
groups andMWNTs backbone, as we previously reported (29).
Fig. 8 Growth inhibition and induction of apoptosis in A549 cells by the co-
delivery of siPLK1 and Dox with DOTAP:chol liposomes (L) or ox-MWNT-
NH3
+-DOTAP:chol hybrid (1-L). Sub-G1 analysis using propidium iodide
staining and flow cytometry was performed 48 h after transfection. Cells
treated with 1 μM of Dox with or without PLK1 silencing with L or 1-L
vectors. siNEG transfected cells were used as negative controls and the tox-
icity of each system was normalized to its siNEG control. Results were
expressed as mean±SD (n=5).
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When 1 μMDox was co-delivered with siPLK1, both car-
riers achieved a synergistic effect which was significantly more
pronounced for 1-L compared to L. These results correlate
well with the enhanced cellular uptake of this system and put
forward hybrid 1-L as a promising system for the co-delivery
of siRNA and a cytotoxic drug and encourage further f-
MWNT-liposome characterization and in vivo studies.
CONCLUSION
Post-transcriptional gene silencing by double-stranded siRNA
constitutes an attractive approach to cancer therapy. However,
in order to become a therapeutic modality, novel delivery sys-
tems which allow direct siRNA translocation into the cytoplasm
of the target cells together with an efficient gene silencing ability
are of the most importance. In the present study, f-MWNT-
cationic liposome hybrids were formulated and tested for their
siRNA binding ability, stability, cellular uptake, in vitro gene
silencing efficiency, induction of apoptosis and siPLK1 and
Dox co-delivery efficiency. DOTAP:chol liposomes were used
as an established model for siRNA delivery and used for com-
parison. All hybrids investigated here were capable of fully
complexing with siRNA at N/P charge ratio of 4:1.
Formulations where the hydrophobic dyeNile Redwas embed-
ded in the lipid bilayer were prepared and interaction between
f-MWNTs and cationic liposomes was confirmed by fluores-
cence spectroscopy. Hybrids prepared with the lower concen-
trations of f-MWNTs showed serum and RNAse stabilities sim-
ilar to those obtained for DOTAP:chol liposomes and therefore
the subsequent studies were carried out with these systems.
Cellular uptake studies in A549-Luc cells demonstrated the
enhanced uptake ability of hybrid 1-L. Moreover, gene silenc-
ing experiments with siLuc and siPLK1 revealed that 1-L was
able to efficiently silence Luciferase and PLK1 genes to levels
comparable to cationic liposomes. In addition, flow cytometry
analysis of sub-G1 population showed that these systems were
capable of inducing cell apoptosis following PLK1 depletion by
siPLK1. When Dox was co-delivered with siPLK1 by these
systems, a synergistic effect was achieved with both liposomal
system L and hybrid 1-L, with the latter yielding a significantly
higher number of apoptotic cells. The results presented here
encourage further testing of 1-L system as a potential vehicle for
the co-delivery of siRNA and cytotoxic drugs. Structural mod-
ifications that favor the in vivo use (e.g., the incorporation of a
fusogenic lipid such as DOPE or PEGylation of the liposome
surface) should be considered.
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